A neurocritical-care cohort showed why treatment timing and selection can change an apparent drug association.
The study followed 66 patients with aneurysmal subarachnoid hemorrhage, half of whom received s-ketamine. Ketamine was often introduced when stronger sedation was needed, in a setting where midazolam was part of combination care. A simple ever-treated comparison did not show a significant difference in spreading-depolarization counts.
Within treated patients, depolarization incidence decreased after ketamine began. Many events had occurred before treatment, making the timing distinction essential.
The study was retrospective, treatment selection reflected clinical need, and co-medication affected the care pathway. It cannot establish a causal benefit from the combination or assign the observed change to midazolam.
For interpretation, align monitoring events with drug start and dose changes rather than grouping every event under eventual treatment status. The paper contributes a timing-sensitive analysis of brain injury care, not proof that sedation success predicts recovery or a universal recommendation for a particular regimen.
Original analysis of the supplied journal article, identified as PMC6937792.